National Institute for Health and Clinical Excellence (NICE)
NICE recommends a weekly injection for treating growth failure in children
This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments
Children being treated for growth disturbance could be spared the pain and discomfort caused by daily injections after NICE recommended a new weekly treatment option called somatrogon.
It will be an option for children and young people aged three years and over who are being treated for a condition called growth disturbance caused by insufficient secretion of growth hormone.
The pituitary gland normally produces human growth hormone, but if this process is disturbed in some way, a child may not grow. A synthetic form of human growth hormone, called somatropin, can help to encourage the body to grow.
At present a daily injection of somatropin is recommended by NICE.
Evidence from clinical trials shows that somatrogon is as effective as one preparation of somatropin.
Somatrogon is the first medicine to be recommended by NICE to go through all steps of its new proportionate approach to technology appraisals project. Around 2,200 children could benefit from this decision.
The evaluation was completed 25 percent faster than the usual cost comparison process and in future NICE expects to increase this to more than 35 percent faster. This was achieved by removing some sections of the process and streamlining others without compromising the rigour of the world-renowned NICE work.
Helen Knight, director of medicines evaluation, at NICE, said: “The recommendation of somatrogon is a welcome development for the care of children with a growth disturbance caused by growth hormone deficiency.
“It is also a milestone for us as an organisation as we’ve been able to evaluate this drug 25 per cent faster and we expect to improve this even further in future topics under this new proportionate way of working.
“We want to get the best care to patients fast, while ensuring value for money for the taxpayer, and at the same time creating useful and useable advice for the NHS.
“NICE is already one of the quickest health technology assessment bodies in the world to appraise new medicines. This pilot will help us maintain a flexible and proportionate approach to appraisals and further improve the speed with which we provide recommendations on promising new treatments.”
The appraisal of somatrogon was completed 7 weeks quicker than our previous cost-comparison process of 29 weeks. Future topics with this new process are expected to be completed 12 weeks faster than previously.
Not all medicines and treatments need the full intensity of our existing appraisals process. Some can be evaluated in a simpler faster way, and by doing this we expect to be able to create extra capacity in our work programme.
In this work we are simplifying, removing, or reconfiguring parts of the appraisals process. In this case instead of a full independent committee reviewing all the evidence and making the recommendations, the chair and vice chair of the committee made the final recommendation following a review of the evidence.
The final draft guidance has been released to the company and registered stakeholders for appeal. If there are no appeals to NICE’s decision, final guidance is expected to be published in February 2023.
Read the final draft guidance for somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]
Original article link: https://www.nice.org.uk/news/article/nice-recommends-a-weekly-injection-for-treating-growth-failure-in-children
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE recommends genetic test to prevent newborn babies going deaf31/03/2023 09:25:00
A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.
Hundreds of people are set to receive the first immunotherapy drug for advanced cervical cancer through the Cancer Drugs Fund30/03/2023 11:05:00
Hundreds of people with cervical cancer are set to receive the first immunotherapy drug for an advanced form of the disease as NICE yesterday (Wednesday 29 March 2023) published the final draft guidance recommending its use in the Cancer Drugs Fund (CDF).
NICE identifies improvements for people with acute kidney injury in updated quality standard23/03/2023 15:30:00
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder in final draft guidance23/03/2023 13:15:00
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE in final draft guidance published today (23 March 2023).
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance21/03/2023 14:15:00
Innovative tests with the potential to help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly could soon be considered for use in the NHS.
NICE recommended weight-loss drug to be made available in specialist NHS services08/03/2023 14:20:00
Thousands of people will soon be able to be prescribed a drug to help them lose weight as part of their treatment in an NHS specialist weight management service.
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE01/03/2023 13:20:00
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance issued today (Wednesday 1 March 2023)
NICE recommends 3 treatments for COVID-19 in final draft guidance21/02/2023 13:05:00
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments, under final draft guidance published by NICE today.
NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines16/02/2023 11:25:00
NICE has today (16 February 2023) issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in adults who are unlikely to have an adequate immune response to COVID-19 vaccination, or who can’t be vaccinated